Loading...
XHKG1801
Market cap7.39bUSD
Dec 23, Last price  
35.05HKD
1D
-0.43%
1Q
-15.34%
IPO
106.66%
Name

Innovent Biologics Inc

Chart & Performance

D1W1MN
XHKG:1801 chart
P/E
P/S
8.69
EPS
Div Yield, %
0.00%
Shrs. gr., 5y
36.04%
Rev. gr., 5y
265.79%
Revenues
6.21b
+36.21%
32,127,15418,538,0009,477,0001,047,525,0003,843,819,0004,269,729,0004,556,380,0006,206,070,000
Net income
-1.03b
L-52.83%
-504,204,000-562,318,000-5,771,492,000-1,776,813,000-998,421,000-3,138,053,000-2,179,270,000-1,027,913,000
CFO
148m
P
-362,993,000-492,270,000-1,016,019,000-1,664,473,000-307,688,000-2,024,843,000-1,918,804,000147,810,000
Earnings
Mar 18, 2025

Profile

Innovent Biologics, Inc. operates as a biopharmaceutical company in China. The company operates a platform for the discovery, development, and manufacture of antibody drug candidates in the fields of oncology, ophthalmology, immunology, and metabolic diseases. Its principal drug candidate is Tyvyt (sintilimab), an anti-PD-1 monoclonal antibody for the treatment of cancer, Hodgkin's lymphoma, and esophageal carcinoma. The company also offers Byvasda for the treatment of several malignant tumors; Halpryza for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia and Wegener's granulomatosis; Pemazyre for the treatment of adults with locally advanced or metastatic cholangiocarcinoma; Olverembatinib for the treatment of adult patients with tyrosine kinase inhibitor; and Cyramza to treat four different types of cancers. In addition, it engages in the development of IBI-301, a rituximab biosimilar for non-Hodgkin's lymphoma; IBI-302, a bispecific antibody fusion protein for ocular fundus disease; IBI-306, a human monoclonal antibody to treat hypercholesterolemia; IBI-310, a recombinant human anti CTLA-4 monoclonal antibody for liver cancer and renal cell carcinoma. Further the company develops IBI-188, an anti-CD47 monoclonal antibody for advanced hematological and solid tumors; IBI-326, a fully human BCMA-CAR T-cell therapy for the treatment of adults with relapsed or refractory multiple myeloma; IBI-376 for the treatment of recurrent or refractory follicular lymphoma; and IBI-112 for the treatment of psoriasis. Additionally, it distributes pharmaceutical products; and provides consultation, and research and development services. The company has strategic collaborations with NeoCura Bio-Medical Technology Co. Ltd.; Roche Group; Ascentage Pharma Group International; Eli Lilly and Company; Roche Group; and Bolt Biotherapeutics, Inc. Innovent Biologics, Inc. was incorporated in 2011 and is headquartered in Suzhou, the People's Republic of China.
IPO date
Oct 31, 2018
Employees
5,144
Domiciled in
CN
Incorporated in
KY

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
6,206,070
36.21%
4,556,380
6.71%
4,269,729
11.08%
Cost of revenue
7,885,371
7,228,463
6,663,300
Unusual Expense (Income)
NOPBT
(1,679,301)
(2,672,083)
(2,393,571)
NOPBT Margin
Operating Taxes
(116,498)
8,801
87,038
Tax Rate
NOPAT
(1,562,803)
(2,680,884)
(2,480,609)
Net income
(1,027,913)
-52.83%
(2,179,270)
-30.55%
(3,138,053)
214.30%
Dividends
Dividend yield
Proceeds from repurchase of equity
2,255,116
2,131,059
3,950,520
BB yield
-3.38%
-4.27%
-5.62%
Debt
Debt current
1,220,330
914,392
387,273
Long-term debt
2,498,796
2,439,191
2,218,318
Deferred revenue
883,277
753,274
Other long-term liabilities
1,222,764
162,305
342
Net debt
(8,044,592)
(5,624,226)
828,928
Cash flow
Cash from operating activities
147,810
(1,918,804)
(2,024,843)
CAPEX
(1,119,385)
(1,381,730)
(1,847,516)
Cash from investing activities
(998,662)
(1,435,185)
(2,698,148)
Cash from financing activities
2,587,257
2,892,082
5,003,361
FCF
(2,158,468)
(2,854,866)
(3,695,711)
Balance
Cash
10,969,629
8,264,594
7,940,893
Long term investments
794,089
713,215
(6,164,230)
Excess cash
11,453,414
8,749,990
1,563,177
Stockholders' equity
(15,767,456)
(15,917,404)
(12,163,261)
Invested Capital
33,138,330
30,860,428
25,651,424
ROIC
ROCE
EV
Common stock shares outstanding
1,559,637
1,490,123
1,455,606
Price
42.75
27.61%
33.50
-30.57%
48.25
-39.69%
Market cap
66,674,482
33.57%
49,919,127
-28.92%
70,232,977
-35.31%
EV
58,629,890
44,294,901
71,061,905
EBITDA
(1,294,198)
(2,352,661)
(2,188,824)
EV/EBITDA
Interest
98,624
101,698
62,464
Interest/NOPBT